PATENT ABSTRACTS

assigned to Institut Pasteur; Universite de Tech- nologic de CompiegneUniversite Pierre Et Marie Cur

The invention concerns hybridomes producing anti-Leishmania monoclonal antibodies which are characterized by their capacity to inhibit the infection of sareomatous cells by the pro- mastigote forms of one or more species of Leish- mania, when the sarcomatous cells are placed in contact with the said promastigote forms pre- incubated with these monoclonal antibodies un- der conditions which, in the absence of the said monoclonal antibodies, would lead to an elevated parasitemia in the said cells. These monoclonal antibodies and the proteins of the parasites that they recognize may be used in the operations of leishmanioses detections.

4 9 9 2 ~ 4

T I S S U E P L A S M I N O G E N A C T I V A T O R A-

C H A I N / U R O K I N A S E B - C H A I N H Y B R I D P R O T E I N

Jeffery H Robinson, Ian Dodd, Epsom, United Kingdom assigned to Beecham Group p 1 c

A fibrinolytically active hybrid protein which comprises one chain of a 2-chain protease linked to a chain of a different 2-chain protease, or to the same chain of the same protease, at least one of the chains in the hybrid protein being derived from a fibrinolytically active protease, such that the hybrid protein has a catalytic site essential for fibrinolytic activity which is optionally blocked by a removable blocking group.

4992363

M E T H O D F O R P R E P A R I N G G L U C O S E F R E E M E D I A F O R

S T O R I N G B L O O D P L A T E L E T S

Scott Murphy assigned to Thomas Jefferson University

Novel methods and storage media for storing platelets in a viable condition for at least five days are disclosed. The disclosed methods com- prise the steps of providing a platelet rich suspen- sion of platelets and blood plasma; extracting supernatant plasma from that suspension to leave between about 1 to 15 mls of plasma per unit of blood platelets with those platelets to pro- duce a concentrated platelet button; adding 40 to

321

70 ml/unit of a glucose free aqueous solution to said concentrated platelet button; agitating the resultant solution to resuspend the platelets to provide a synthetic suspension of those platelets; and storing that synthetic suspension in an oxy- gen permeable container at about 22 degrees C. until needed for use. Two preferred glucose free aqueous platelet storage media are disclosed which generally comprise sodium citrate, sodium chloride, potassium chloride, and either sodium phosphate or calcium chloride, but not both. The subject media also optionally comprise magnesium sulfate. Results comparable to storing blood platelets in plasma are disclosed using media which free plasma for other uses and which may reduce the risk of disease transmis- sion from platelet infusion.

4 9 9 2 3 ~

F E R M E N T A T I O N P R O C E S S F O R G L Y C O P E P T I D E A N T I B I O T I C

Hiroshi Maeda, Junsuke Tone, John C Rud- dock, Kelvin S Holdom, Chita, Japan assigned to Pfizer Inc

A new glycopeptide antibiotic UK-68,597 can be prepared by submerged aerobic propagation in aqueous nutrient media of Actinoplanes sp. ATCC 53533. The antibiotic and its cationic salts are active against a variety of micro- organisms and are effective in controlling coc- cidiosis, enteritis, swine dysentery and theileriosis as well as being effective in promo- tion of growth and/or improving efficiency of feed utilization in poultry, swine and ruminants.

4992374

M U T A N T V A C C I N I A V I R U S A N D P R O C E S S F O R P R O D U C T I O N

T H E R E O F

Masanobu Sugimoto, Fukumi Nishimaki, Tadashi Maruyama, Keizaburo Miki, Michio Morita, Kazuyoshi Suzuki, Shiki, Japan as- signed to Toa Nenryo Kogyo Kabushiki Kaisha; Chiba Prefectu

An improved mutant vaccinia virus providing a pock and plaque size on RKI3 cells that is ap- proximately the same as those of the Lister orig- inal, having a proliferation potency on YTV cells that is approximately the same as that of the Lister original, and having a neurovirulence, as- sessed by a recovery of an intrabrain virus, that is